Table 1 Patient characteristics and SUVmax comparisons between or among groups
Characteristics | No. of patients (n=134) | Baseline SUVmax | ||
|---|---|---|---|---|
Median | IQR | Pvalue* | ||
Age | ||||
≤ 50 | 63 (47.0%) | 6.60 | 5.10–9.10 | 0.616 |
> 50 | 71 (53.0%) | 6.85 | 4.80–9.80 | |
Menstruation status | ||||
Pre-menopausal | 53 (39.6%) | 6.60 | 5.10–9.00 | 0.685 |
Post-menopausal | 81 (60.4%) | 6.85 | 4.85–9.75 | |
Histology | ||||
IDC | 124 (92.5%) | 6.95 | 5.03–9.66 | 0.131 |
ILC | 6 (4.5%) | 6.33 | 5.15–9.90 | |
Others | 4 (3.0%) | 4.65 | 3.10–5.68 | |
Luminal subtype | ||||
Luminal A | 75 (56.0%) | 6.75 | 5.10–9.20 | 0.744 |
Luminal B | 59 (44.0%) | 7.00 | 4.80–10.00 | |
Adjuvant/neoadjuvant therapy | ||||
Only CT (± RT) | 4 (3.0%) | 6.68 | 5.76–9.05 | 0.887 |
Only HT (± RT) | 6 (4.5%) | 6.15 | 3.74–9.85 | |
CT + HT (± RT) | 101 (75.4%) | 6.75 | 5.15–9.25 | |
Therapy with TT | 21 (15.7%) | 7.00 | 4.75–10.25 | |
No | 2 (1.5%) | 5.50 | 4.50–6.50 | |
Relapse-free interval | ||||
≤ 2 years | 48 (35.8%) | 6.25 | 4.81–9.20 | 0.592 |
> 2 years | 86 (64.2%) | 7.00 | 5.18–9.59 | |
No. of metastatic sites | ||||
1 | 53 (39.6%) | 6.10 | 4.60–9.08 | 0.002 |
2 | 37 (27.6%) | 6.25 | 4.70–8.15 | |
≥ 3 | 44 (32.8%) | 8.40 | 6.21–10.73 | |
Visceral metastasis | ||||
Yes | 64 (47.8%) | 7.60 | 5.53–10.28 | 0.009 |
No | 70 (52.2%) | 6.32 | 4.80–7.73 | |
Only bone | 20 (14.9%) | 4.85 | 3.58–7.10 | 0.063 |
Others | ||||
Only lymph node | 18 (13.4%) | 6.37 | 5.20–7.78 | |
Only skin & soft tissue | 5 (3.7%) | 10.1 | 4.45–10.30 | |
Mixed | 27 (20.1%) | 6.70 | 5.10–7.70 | |